Heather D. Brooks, Bonnie S. Glisson, B. Nebiyou Bekele, Lawrence E. Ginsberg, Adel El-Naggar, Kirk S. Culotta, Naoko Takebe, John Wright, Hai T. Tran and Vassiliki A. Papadimitrakopoulou Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma Cancer 117
Article first published online: 29 NOV 2010 | DOI: 10.1002/cncr.25769
This is a report of what to the authors'; knowledge is the first phase 2 study of dasatinib in head and neck cancer accompanied by extensive serum cytokine and angiogenic factor profiling. The activity of dasatinib in patients with metastatic/recurrent head and neck cancer is modest and administration via percutaneous feeding tube feasible, and prognostic biologic parameters for patient outcome have been identified.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field